Table 1.
Clinical and demographic characteristics of RA patients prior to pneumococcal vaccination
| RA control | MTX group | ABT group | p Values between treatment groups | |
|---|---|---|---|---|
| n = 35 | n = 55 | n = 21 | ||
| Male/female | 12/23 | 11/44 | 4/17 | 0.251 |
| Age, mean ± SD (years) | 70.5 ± 10.8 | 63.8 ± 11.5 | 59.8 ± 12.0 | 0.002 |
| Weight, mean ± SD (Kg) | 53.3 ± 9.5 | 52.9 ± 11.8 | 55.2 ± 10.1 | 0.501 |
| BMI, mean ± SD | 21.8 ± 3.5 | 21.7 ± 3.7 | 23.2 ± 4.9 | 0.344 |
| RA duration, mean ± SD (years) | 11.7 ± 12.5 | 14.1 ± 10.9 | 13.5 ± 11.2 | 0.144 |
| MTX dose, mean ± SD (mg/week) | - | 7.8 ± 2.4 | 7.2 ± 3.4(15/21) | - |
| ABT dose, mean ± SD (mg/4 week) | - | - | 547.6 ± 127.9 | - |
| Use of prednisolone, number of patients (%) | 21 (60.0) | 30 (54.5) | 13(61.9) | 0.798 |
| Prednisolone dose, mean ± SD (mg/day) | 6.06 ± 4.23 | 4.98 ± 2.97 | 5.04 ± 2.85 | 0.769 |
| DAS28(CRP), mean ± SD | 2.79 ± 1.17 | 2.61 ± 0.98 | 2.48 ± 1.31 | 0.565 |
| SDAI, mean ± SD | 9.03 ± 6.32 | 8.15 ± 7.33 | 8.32 ± 7.29 | 0.593 |
| CDAI, mean ± SD | 7.83 ± 5.40 | 7.46 ± 6.73 | 7.87 ± 6.54 | 0.721 |
| IP (%) | 6 (17.1) | 7 (12.7) | 3(14.3) | 0.844 |
| COPD (%) | 3 (8.6) | 1 (1.8) | 2(9.5) | 0.251 |
| Smoking history (%) | 10(28.6) | 13(23.6) | 6(28.6) | 0.839 |
Data were obtained immediately before pneumococcal vaccination. p values between treatment groups were determined using the Kruskal-Wallis test. p values were calculated with the chi-square test for qualitative data. RA rheumatoid arthritis, MTX methotrexate, ABT abatacept, BMI body mass index, DAS28 Disease Activity Score 28, SDAI simplified disease activity index, CDAI clinical disease activity index, IP interstitial pneumonia, COPD chronic obstructive pulmonary disease